Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study

Frederick R. Singer, Paul S. Ritch, Thomas E. Lad, Q. Scott Ringenberg, Joan H. Schiller, Robert R. Recker, Elisabeth Ryzen, Claude S. Arnaud, Michael D. Draper, Gordon J. Strewler, John M. Bennett, Joanne R. Carignan, Craig S. McCune, Raman Qazi, Patrick J. Byrne, Peder Charles, Claus Hasling, Leif Mosekilde, Ronald C. DeConti, Gregory R. HarperJohn Horton, John C. Ruckdeschel, Alexander S. Spiers, Lee M. Zehngebot, David S. Ettinger, Martin D. Abeloff, Michael D. Green, Howard S. Hochster, Harold A. Harvey, Allan Lipton, Mary A. Simmonds, Subhash Kukreja, Daniel Shevrin, Michael R. McClung, Nancy Kane-Johnson, Eric S. Orwoll, Lawrence C. Panasci, Walter A. Brzezinski, Tom Anderson, Marjorie A. Vukelich, Al B. Benson, Thomas E. Davis, James K. Willson, Manuel Fernandez, Robert K. Rude

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalArchives of Internal Medicine
Volume151
Issue number3
DOIs
StatePublished - Mar 1991

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study'. Together they form a unique fingerprint.

  • Cite this

    Singer, F. R., Ritch, P. S., Lad, T. E., Ringenberg, Q. S., Schiller, J. H., Recker, R. R., Ryzen, E., Arnaud, C. S., Draper, M. D., Strewler, G. J., Bennett, J. M., Carignan, J. R., McCune, C. S., Qazi, R., Byrne, P. J., Charles, P., Hasling, C., Mosekilde, L., DeConti, R. C., ... Rude, R. K. (1991). Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study. Archives of Internal Medicine, 151(3), 471-476. https://doi.org/10.1001/archinte.1991.00400030039007